ConductScience.org, home

Paper39200006

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martín-Cerezuela M and 10 others. Antibiotics (Basel), 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety. Papers, record 39200006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39200006

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.29, provisional
iCite
Revised in PubMed
2024-09-01
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martín-Cerezuela MMaríahttps://orcid.org/0000-0002-8929-1654
2Maya Gallegos CCristina
3Marqués-Miñana MRMaría Remedios
4Broch Porcar MJMaría Jesúshttps://orcid.org/0000-0002-6267-6378
5Cruz-Sánchez AAndrés
6Mateo-Pardo JCJuan Carlos
7Peris Ribera JEJosé Esteban
8Gimeno RRicardo
9Castellanos-Ortega ÁÁlvaro
10Poveda Andrés JLJosé Luishttps://orcid.org/0000-0003-1800-6198
11Ramírez Galleymore PPaulahttps://orcid.org/0000-0002-7598-3350

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137808914Mucormycosis in 2023: an update on pathogenesis and management.Front Cell Infect Microbiol2023https://conductscience.org/library/papers/37808914PubMed
231767725Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31767725PubMed
333922419Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole.Antibiotics (Basel)2021https://conductscience.org/library/papers/33922419PubMed
433333012Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.Lancet Infect Dis2021https://conductscience.org/library/papers/33333012PubMed
536978342Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria.Antibiotics (Basel)2023https://conductscience.org/library/papers/36978342PubMed
629544767Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clin Microbiol Infect2018https://conductscience.org/library/papers/29544767PubMed
737508181Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review.Antibiotics (Basel)2023https://conductscience.org/library/papers/37508181PubMed
832535847Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.J Pharmacokinet Pharmacodyn2020https://conductscience.org/library/papers/32535847PubMed
935726095Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.J Antimicrob Chemother2022https://conductscience.org/library/papers/35726095PubMed
1031119272Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.J Antimicrob Chemother2019https://conductscience.org/library/papers/31119272PubMed
1128355463Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.J Antimicrob Chemother2017https://conductscience.org/library/papers/28355463PubMed
1229725999Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clin Pharmacokinet2018https://conductscience.org/library/papers/29725999PubMed
1326684607Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.Lancet2016https://conductscience.org/library/papers/26684607PubMed
1433361296Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33361296PubMed
1537700457Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19.Mycoses2023https://conductscience.org/library/papers/37700457PubMed
1635535740Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.Mycoses2022https://conductscience.org/library/papers/35535740PubMed
1729735569Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29735569PubMed
1836183212Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.Farm Hosp2022https://conductscience.org/library/papers/36183212PubMed
1930851209Impact of voriconazole plasma concentrations on treatment response in critically ill patients.J Clin Pharm Ther2019https://conductscience.org/library/papers/30851209PubMed
2036354913Survival Outcome of Empirical Antifungal Therapy and the Value of Early Initiation: A Review of the Last Decade.J Fungi (Basel)2022https://conductscience.org/library/papers/36354913PubMed

See all 37 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42984876Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42984876PubMed
42903265Population pharmacokinetic model library for isavuconazole: development and quality control.Front Microbiol2026https://conductscience.org/library/papers/42903265PubMed
42797225Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study.Pharmaceutics2026https://conductscience.org/library/papers/42797225PubMed
42394820
Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42394820PubMed
42088097Characterization of isavuconazole pharmacokinetics and pharmacodynamics in a real-life cohort.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42088097PubMed
41919159Therapeutic drug monitoring-guided optimization of isavuconazole dose for ICU patients with refractory pulmonary aspergillosis: case report.Front Med (Lausanne)2026https://conductscience.org/library/papers/41919159PubMed
41515529Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel)2025https://conductscience.org/library/papers/41515529PubMed
41311305Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS).Mycoses2025https://conductscience.org/library/papers/41311305PubMed
41059267Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study.JAC Antimicrob Resist2025https://conductscience.org/library/papers/41059267PubMed
41024947Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review.World J Nephrol2025https://conductscience.org/library/papers/41024947PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39200006

GET https://conductscience.org/api/papers/v1/39200006/references?page=2